Recurrent EML4–ALK-associated lung adenocarcinoma with a slow clinical course
| Autor: | Kouzo Yamada, Haruhiko Nakayama, Yuji Sakuma, Fumihiro Oshita, Tomoyuki Yokose, Shoichi Matsukuma, Haruhiro Saito, Kazumasa Noda, Chikako Hasegawa, Tetsuro Kondo, Youichi Kameda, Hiroyuki Ito, Masahiro Tsuboi, Shuji Murakami |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
Pulmonary and Respiratory Medicine Cancer Research Pathology medicine.medical_specialty Lung Neoplasms Time Factors Oncogene Proteins Fusion Pleural Neoplasms Adenocarcinoma medicine.disease_cause Diagnosis Differential Proto-Oncogene Proteins p21(ras) Proto-Oncogene Proteins hemic and lymphatic diseases Biomarkers Tumor medicine Humans Anaplastic lymphoma kinase Lung cancer Lung Signet ring cell business.industry Respiratory disease Cancer medicine.disease digestive system diseases ErbB Receptors medicine.anatomical_structure Oncology Mutation ras Proteins Female KRAS Neoplasm Recurrence Local Tomography X-Ray Computed business |
| Zdroj: | Lung Cancer. 69:361-364 |
| ISSN: | 0169-5002 |
| Popis: | The fusion gene EML4-ALK (echinoderm microtubule-associated protein-like 4 gene and the anaplastic lymphoma kinase gene) was recently identified as a novel genetic alteration in non-small-cell lung cancer. The clinicopathological features of EML4-ALK-positive adenocarcinoma are reported to include its high incidence in young, non-smoking patients, tumors that show distinct solid or acinar growth patterns with or without signet-ring cell histology, and its mutually exclusive occurrence with mutations in EGFR and KRAS. However, the clinical findings have not been well described. Here, we report a case of EML4-ALK-positive lung adenocarcinoma that showed multiple metachronous lesions on the pleura and pulmonary field, suspected to be a recurrence of lung adenocarcinoma after a 20-year disease-free interval. The slow clinical course may be characteristic of EML4-ALK-positive lung adenocarcinoma. Therefore, long-term observation of patients with EML4-ALK-positive lung adenocarcinomas is required after surgery. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect